190 related articles for article (PubMed ID: 18387679)
21. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
22. Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain.
Hsieh SM; Chen SY; Sheu GC; Hung MN; Chou WH; Chang SC; Hsu KH
Vaccine; 2006 Jan; 24(4):510-5. PubMed ID: 16139395
[TBL] [Abstract][Full Text] [Related]
23. Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.
Hughes CM; Newman FK; Davidson WB; Olson VA; Smith SK; Holman RC; Yan L; Frey SE; Belshe RB; Karem KL; Damon IK
Clin Vaccine Immunol; 2012 Jul; 19(7):1116-8. PubMed ID: 22593237
[TBL] [Abstract][Full Text] [Related]
24. Establishment of a neutralization test involving reporter gene-expressing virus-like particles of tick-borne encephalitis virus.
Yoshii K; Ikawa A; Chiba Y; Omori Y; Maeda J; Murata R; Kariwa H; Takashima I
J Virol Methods; 2009 Oct; 161(1):173-6. PubMed ID: 19481114
[TBL] [Abstract][Full Text] [Related]
25. The persistence of humoral and cellular immunities more than three decades after smallpox vaccination.
Kim SH; Yeo SG; Park KH; Bang JW; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
Clin Microbiol Infect; 2007 Jan; 13(1):91-3. PubMed ID: 17184294
[TBL] [Abstract][Full Text] [Related]
26. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
[TBL] [Abstract][Full Text] [Related]
27. Vaccinia virus-based expression of gp120 and EGFP: survey of mammalian host cell lines.
Bleckwenn NA; Bentley WE; Shiloach J
Biotechnol Prog; 2005; 21(1):186-91. PubMed ID: 15903257
[TBL] [Abstract][Full Text] [Related]
28. Dose-dependent neutralizing-antibody responses to vaccinia.
Belshe RB; Newman FK; Frey SE; Couch RB; Treanor JJ; Tacket CO; Yan L
J Infect Dis; 2004 Feb; 189(3):493-7. PubMed ID: 14745707
[TBL] [Abstract][Full Text] [Related]
29. Absence of detectable viremia in plasma and peripheral blood mononuclear cells from smallpox vaccinees: implications for blood safety.
Srinivasan K; Akolkar PN; Taffs RE; Hewlett IK
Transfusion; 2006 Sep; 46(9):1589-92. PubMed ID: 16965588
[TBL] [Abstract][Full Text] [Related]
30. Humoral Immunity to Primary Smallpox Vaccination: Impact of Childhood versus Adult Immunization on Vaccinia Vector Vaccine Development in Military Populations.
Slike BM; Creegan M; Marovich M; Ngauy V
PLoS One; 2017; 12(1):e0169247. PubMed ID: 28046039
[TBL] [Abstract][Full Text] [Related]
31. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
33. Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.
Newman FK; Frey SE; Blevins TP; Mandava M; Bonifacio A; Yan L; Belshe RB
J Clin Microbiol; 2003 Jul; 41(7):3154-7. PubMed ID: 12843056
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a vaccinia virus strain used to produce smallpox vaccine in Argentina between 1937 and 1970.
Lewis A; Bok K; Perez O; DeFillippo J; Paolazzi C; Gomez JA
Arch Virol; 2005 Jul; 150(7):1485-91. PubMed ID: 15750861
[TBL] [Abstract][Full Text] [Related]
35. Plaque-reduction assays for human and simian immunodeficiency virus neutralization.
Nordqvist A; Fenyö EM
Methods Mol Biol; 2005; 304():273-85. PubMed ID: 16061983
[TBL] [Abstract][Full Text] [Related]
36. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.
Hatakeyama S; Moriya K; Saijo M; Morisawa Y; Kurane I; Koike K; Kimura S; Morikawa S
Clin Diagn Lab Immunol; 2005 Apr; 12(4):520-4. PubMed ID: 15817760
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies.
Putnak JR; de la Barrera R; Burgess T; Pardo J; Dessy F; Gheysen D; Lobet Y; Green S; Endy TP; Thomas SJ; Eckels KH; Innis BL; Sun W
Am J Trop Med Hyg; 2008 Jul; 79(1):115-22. PubMed ID: 18606774
[TBL] [Abstract][Full Text] [Related]
38. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of smallpox vaccines using variola neutralization.
Damon IK; Davidson WB; Hughes CM; Olson VA; Smith SK; Holman RC; Frey SE; Newman F; Belshe RB; Yan L; Karem K
J Gen Virol; 2009 Aug; 90(Pt 8):1962-1966. PubMed ID: 19339477
[TBL] [Abstract][Full Text] [Related]
40. Comparison of methods for detection of vaccinia virus in patient specimens.
Fedorko DP; Preuss JC; Fahle GA; Li L; Fischer SH; Hohman P; Cohen JI
J Clin Microbiol; 2005 Sep; 43(9):4602-6. PubMed ID: 16145113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
